Vincent van der Mark joined the Merck Ventures Healthcare team as an Analyst in August 2016. He previously obtained a MSc in Biomedical Sciences (University of Amsterdam) and pursued a PhD in Biochemistry (University of Amsterdam), which focused on the physiological role of phospholipid flippases in the intestines and macrophages. Afterwards he performed postdoctoral work on the validation and optimization of 3D cell culture systems and liver cells as predictive models for drug metabolism and toxicity studies. This work resulted in a patent application and exploratory commercialization. Vincent is based in Amsterdam.